Literature DB >> 12471401

Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren.

John V Bennett1, Jorge Fernandez de Castro, Jose Luis Valdespino-Gomez, Ma de Lourdes Garcia-Garcia, Rocio Islas-Romero, Gabriela Echaniz-Aviles, Aida Jimenez-Corona, Jaime Sepulveda-Amor.   

Abstract

OBJECTIVE: To compare antibody responses and side-effects of aerosolized and injected measles vaccines after revaccination of children enrolling in elementary schools.
METHODS: Vaccines for measles (Edmonston-Zagreb) or measles-rubella (Edmonston-Zagreb with RA27/3) were given by aerosol or injection to four groups of children. An additional group received Schwarz measles vaccine by injection. These five groups received vaccines in usual standard titre doses. A sixth group received only 1000 plaque-forming units of Edmonston-Zagreb vaccine by aerosol. The groups were randomized by school. Concentrations of neutralizing antibodies were determined in blood specimens taken at baseline and four months after vaccination from randomized subgroups (n = 28-31) of children in each group.
FINDINGS: After baseline antibody titres were controlled for, the frequencies of fourfold or greater increases in neutralizing antibodies did not differ significantly between the three groups that received vaccine by aerosol (range 52%-64%), but they were significantly higher than those for the three groups that received injected vaccine (range 4%-23%). Mean increases in titres and post-vaccination geometric mean titres paralleled these findings. Fewer side-effects were noted after aerosol than injection administration of vaccine.
CONCLUSION: Immunogenicity of measles vaccine when administered by aerosol is superior to that when the vaccine is given by injection. This advantage persists with aerosolized doses less than or equal to one-fifth of usual injected doses. The efficacy and cost-effectiveness of measles vaccination by aerosol should be further evaluated in mass campaigns.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471401      PMCID: PMC2567652     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  23 in total

Review 1.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

2.  Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques.

Authors:  Wen-Hsuan Lin; Diane E Griffin; Paul A Rota; Mark Papania; Stephen P Cape; David Bennett; Brian Quinn; Robert E Sievers; Charles Shermer; Kenneth Powell; Robert J Adams; Steven Godin; Scott Winston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 3.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

4.  Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice.

Authors:  Jennifer Humberd Smith; Paula Brooks; Scott Johnson; S Mark Tompkins; Koren M Custer; Debra L Haas; Raydel Mair; Mark Papania; Ralph A Tripp
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

5.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

Review 6.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

Review 8.  An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children.

Authors:  Daisy Higginson; Evropi Theodoratou; Harish Nair; Tanvir Huda; Lina Zgaga; Suresh S Jadhav; Saad B Omer; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

9.  Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.

Authors:  Diane L Bolton; Sampa Santra; Cindy Swett-Tapia; Jerome Custers; Kaimei Song; Harikrishnan Balachandran; Linh Mach; Hussein Naim; Pamela A Kozlowski; Michelle Lifton; Jaap Goudsmit; Norman Letvin; Mario Roederer; Katarina Radošević
Journal:  Vaccine       Date:  2012-06-22       Impact factor: 3.641

10.  Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Authors:  Joshua M DiNapoli; Jerrold M Ward; Lily Cheng; Lijuan Yang; Subbiah Elankumaran; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  Vaccine       Date:  2009-01-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.